



Socioeconomic

Population¹

527 080 (2024)

Life expectancy at birth²

81 years (2023)

GDP/capita (current US\$)³



US\$ 13 215.5 (2023)



Spending on health

Current health expenditure
(CHE)/capita (current US\$)⁴

US\$ 1150.69 (2022)

9.65% (2022)
Current health
expenditure as share
of GDP⁴78.15% (2022)
Government health
expenditure (% of CHE)⁴
17.54% (2022)
Out-of-pocket
expenditure (% of CHE)⁴


Spending on pharmaceuticals

Government pharmaceutical
expenditure

No data

Government pharmaceutical
expenditure/capita

No data

Pharmaceutical
expenditure (% of CHE)56% (2019)
Pharmaceutical
expenditure (% of CHE)⁵

Medical and pharmacy workforce

Medical doctors/
10 000 population⁶

22.4 (2020)

Pharmacists/
10 000 population⁶

7.01 (2020)

Pharmacy education
accreditation⁷

Yes

Continuing professional
development for pharmacists⁷

Partly



Pharmaceutical legislation and policy

- 2007 • National Medicines Policy
- 2009 • National Medication Practice Standards
- 2014 • Health Services Act (Law No.29/2014);
Medicine Regulation No: R-46/2014
- 2015 • Healthcare Professionals Act (13/2015)
- 2017–2021 • National action plan for containment
of AMR
- 2020 • Guideline on Good Manufacturing
Practices; Guideline of Good Reliance
Practice for Regulation of Medicines

- 2021 • Guidelines on Product Registration and
Approval for Medicines
- 2022 • Guideline on Regulation of Veterinary
Medicines Import and Pharmacy registration
- 2024 • Guideline for Product Registration including
Emergency Use Authorization V5; Guideline
for Pre-Authorization Approval of Medicines
V3; Guideline on Pharmaceutical Inspection
V3; National Medication Practice Standard V2
- 2024–2029 • National Action Plan for AMR
- 2024–2030 • National Medicine Policy
- 2025 • Guideline on Approving the Import of
Medicines from Accredited Hospital V2;
Guideline on Medicine Disposal V4



Intellectual property rights



TRIPS flexibilities
incorporated into
the law



TRIPS flexibilities
utilized

No data



Rational use and antimicrobial resistance

% of market share of
non-EML products

No data

WHO Global Antimicrobial Resistance and
Use Surveillance System enrollment⁸:
Yes, 2020

Total consumption of antibiotics:
No data

FDC sales in the
private market

No data

Number of antibiotics on the private market

	Total	AWaRe			Not recommended
		Access	Watch	Reserve	
Single drugs			No data		
FDCs			No data		

Market
entryNational Regulatory Authority²

Maldives Food and Drug Authority (MFDA)

Website: <https://health.gov.mv/en/departments/maldives-food-and-drug-authority>

Staff: No data

Annual budget: US\$ No data

Products regulated⁹

☒ Medicines

☒ Biologicals

☒ Medical
devices

☒ Traditional
medicines

Licensing of establishments¹⁰

☐ Manufacturers

☐ Importers

☐ Exporters

☐ Wholesellers

☐ Distributors

☐ Retailers

National Medicines Quality Control Laboratory⁷

1

☐ ISO 17025
certified⁷

☐ WHO
prequalified⁷

Rational
selectionBody responsible for selection of medical products¹¹

Maldives Food and Drug Authority (MFDA)

☐ HTA used in the selection process

☒ NEML incorporated AWaRE list

☒ Medicines listed by level of care

☐ Traditional medicines included

National Essential Medicines List (number of active ingredient)¹²

2009

2013

2016

2018

2021

428 medicines

2023

438 medicines

National Medicines Formulary¹⁰

No data

National Essential Diagnostics List¹⁰: No data

Purchasing



Public sector

☒ Procurement^{7,10}: Centralized

Agency responsible for procurement: State Trading Organization for public sector pharmacies, Ministry of Health (for government health facilities in hospital use medicines)

LMIS used: No data

Frequency of tender: No data

Private sector

☒ Social Health Insurance

Name of SHI scheme¹³: Social Health Insurance Scheme (Aasandha)

Population coverage: All Maldivians

Number of products covered¹⁰: 3428

Pricing regulation

Pricing regulatory authority¹¹

Maldives Food and Drug Authority (MFDA)

Public sector

Tendering¹⁴: Yes

Private sector

Maximum retail price¹⁴: Yes (implementation not yet in place)

Number of price controlled products¹⁴: 3523 on reimbursement list

2015

Ministry of Health
decree 98/2015

Market distribution



Estimated pharmaceutical market value

No data

Public

Tertiary hospitals¹⁵: 4

Secondary hospitals: 14

PHC facilities: 165

Private

Manufacturers: None

Importers: 73

Wholesellers/distributors: 76

Retail pharmacies: 453

Market exit



Legal provision for

☒ Cancellation of licences of pharmaceutical establishments

☒ Cancellation of marketing authorization of products

☒ Initiating product recalls and withdrawals

References

1. World Bank, DataBank, Health Nutrition and Population Statistics, Maldives, <https://data.worldbank.org/indicator/SP.POP.TOTL?locations=MV>, accessed 25 August 2025.
2. World Bank, Life expectancy at birth, total (years), Maldives, <https://data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=MV>, accessed 26 August 2025.
3. World Bank, GDP per capita, Maldives, <https://data.worldbank.org/indicator/NY.GDP.PCAP.CD?locations=MV>, accessed 28 August 2025.
4. World Health Organization Global Health Expenditure database, <https://www.who.int/data/gho>, accessed 25 August 2025.
5. Maldives Bureau of Statistics, Household Income and Expenditure Survey (2019), <https://statisticsmaldives.gov.mv/nbs/wp-content/uploads/2021/05/HIES2019-Expenditure.pdf>, accessed 28 August 2025.
6. World Health Organization, Global Health Observatory, Health Workforce, <https://www.who.int/data/gho/data/themes/topics/health-workforce>, accessed 14 August 2025.
7. World Health Organization. Regional Office for South-East Asia. (2021). Access to medical products in the South-East Asia Region 2021: Review of progress. World Health Organization. Regional Office for South-East Asia. <https://www.who.int/publications/i/item/9789290228967.10>.
8. World Health Organization, Global Antimicrobial Resistance and Use Surveillance System (GLASS), <https://www.who.int/initiatives/glass/country-participation>, accessed 15 August 2025.
9. World Health Organization, Regional Office for South-East Asia, Access to medical products in the South-East Asia Region, 2023, <https://iris.who.int/handle/10665/373774>, accessed 15 August 2025.
10. Reported by the Ministry of Health, Maldives, 2023 (internal communication)
11. Ministry of Health, Maldives Food and Drug Authority, <https://health.gov.mv/en/departments/maldives-food-and-drug-authority>, accessed 28 August 2025.
12. Maldives Food and Drug Authority, Essential Medicines List 2021, <https://health.gov.mv/storage/uploads/pDqKPWoO/piklrly.pdf>, accessed 28 August 2025.
13. Maldives National Social Protection Agency, Social Health Insurance Scheme (Aasandha), <https://www.nspa.gov.mv/v2/index.php/aasandha-2/>, accessed 28 August 2025.
14. World Health Organization, Medicines' price regulatory interventions in the WHO South-East Asia Region: Policy review and recommendations for further research, https://cdn.who.int/media/docs/default-source/searo/hsd/edm/medicines-price-regulatory-interventions-in-the-who-south-east-asiaregion-policy-review-and-recommendations-for-further-research.pdf?sfvrsn=5ff3b867_1&download=true, accessed 15 August 2025.
15. Ministry of Health, Maldives, <https://health.gov.mv/en>, accessed 28 August 2025.